A slow disengagement from platinum-based chemotherapy for patients with advanced non-small cell lung cancer

Cancer Biol Ther. 2005 Dec;4(12):1316-7. doi: 10.4161/cbt.4.12.2488. Epub 2005 Dec 9.

Authors

Marc S Ballas¹, Phillip A Dennis

Affiliation

¹ Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20889, USA.

PMID: 16434876
DOI: 10.4161/cbt.4.12.2488

No abstract available

Publication types

Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Camptothecin / administration & dosage
Camptothecin / adverse effects
Camptothecin / analogs & derivatives
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / mortality*
Carcinoma, Non-Small-Cell Lung / pathology
Diarrhea / chemically induced
Drug Administration Schedule
Humans
Irinotecan
Lung Neoplasms / drug therapy*
Lung Neoplasms / mortality*
Lung Neoplasms / pathology
Maximum Tolerated Dose
Neutropenia / chemically induced
Paclitaxel / administration & dosage
Paclitaxel / adverse effects
Platinum / therapeutic use*
Survival Rate
Time Factors

Substances

Platinum
Irinotecan
Paclitaxel
Camptothecin